Scilex Holding Company (SCLX)
NASDAQ: SCLX · Real-Time Price · USD
0.423
+0.011 (2.74%)
At close: Feb 3, 2025, 4:00 PM
0.410
-0.013 (-3.17%)
After-hours: Feb 3, 2025, 7:50 PM EST
Scilex Holding Company Revenue
Scilex Holding Company had revenue of $14.44M in the quarter ending September 30, 2024, with 42.69% growth. This brings the company's revenue in the last twelve months to $55.15M, up 22.02% year-over-year. In the year 2023, Scilex Holding Company had annual revenue of $46.74M with 22.90% growth.
Revenue (ttm)
$55.15M
Revenue Growth
+22.02%
P/S Ratio
0.84
Revenue / Employee
$525,257
Employees
105
Market Cap
77.55M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.74M | 8.71M | 22.90% |
Dec 31, 2022 | 38.03M | 6.72M | 21.45% |
Dec 31, 2021 | 31.32M | 7.76M | 32.92% |
Dec 31, 2020 | 23.56M | 2.53M | 12.01% |
Dec 31, 2019 | 21.03M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
SCLX News
- 3 days ago - Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 - GlobeNewsWire
- 13 days ago - Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - GlobeNewsWire
- 13 days ago - Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 - GlobeNewsWire
- 13 days ago - Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC - GlobeNewsWire
- 13 days ago - Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024 - GlobeNewsWire
- 18 days ago - Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults - GlobeNewsWire
- 5 weeks ago - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025 - GlobeNewsWire
- 7 weeks ago - Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering - GlobeNewsWire